Hereditary Testing Market Size Projected to Reach $17.57 billion by 2034 | 8.8%

Genetic tests, a standard medical procedure in kits and panels, evaluate human genetics, lifestyle, cancer, and cardiovascular conditions. The patient's blood is drawn for the test and then processed through laboratory equipment for analysis. The key factors driving market expansion are increasing the frequency of inherited problems, heightened public awareness of the harmful implications, advances in genetic analysis, and the emergence of rare diseases.

Market Dynamics

Rapidly Expanding Fields of Reproductive Genetics and an Increase in DNA Test Kit Sales Drive the Global Market

The rapidly expanding field of reproductive genetic health is one of the key factors influencing this market. Important players in the genetic testing for inherited disorders in women's health, like Natera, have reported an ongoing rise in the overall number of tests carried out. This reflects the general public's growing acceptance of genetic testing, accelerating revenue growth. A growth in DNA screening kit purchases is a consequence of the market's increasing demand for genetic testing. For instance, the Virginia Department of General Services Division of Integrated Laboratory Facilities tested 7,867 infants for more than 31 genetic and metabolic disorders. Changes to genetic testing techniques have led to the clinical application of multigene panel screening for inherited disorders. Technological providers play a crucial part in the market by bolstering distribution services and enhancing technical efficacy.

New Medical Diagnostics and Improved Health Results Create Tremendous Opportunities

Technology service providers help the market grow by improving distribution services and raising technical efficacy. Corporations use a cloud-based distribution approach to make bioinformatics technologies accessible to other universities. Approximately fourteen licensees have started aggressively marketing non-invasive prenatal testing devices using constellation software. Furthermore, the lack of adequate testing regulation is a critical issue that requires immediate attention. Despite these challenges, the genetic testing market is growing due to the advantages of these ground-breaking tests and improved healthcare outcomes.

Regional Analysis

Europe is the most significant revenue shareholder and is anticipated to maintain its lead during the forecast period. This can be ascribed to significant actors conducting genetic tests, the widespread acceptance of modern treatments, and recommendations offered by government bodies to ensure the quality of services supplied by hereditary testing companies. Many essential companies in the United States of America and several nations in Europe, Asia Pacific, and other regions are currently offering various hereditary tests. Quest and Blueprint Genetics will facilitate improvements in patient care and advances in pharmaceutical research and development by improving access to actionable insights into genetic and uncommon illnesses.

Key Highlights

• The global hereditary testing market size was valued at $13.57 billion in 2025 and is projected to grow from $14.76 billion in 2026 to $28.97 billion by 2034, registering a CAGR of 8.79% during the forecast period (2026–2034).
• Based on disease type, the market is segmented into hereditary cancer testing and hereditary non-cancer testing. The hereditary non-cancer testing segment dominates the global market and is anticipated to grow at a substantial CAGR during the forecast period.
• Europe is the most significant revenue shareholder and is anticipated to maintain its lead during the forecast period.

Market Segments

1. By Disease Type
   1. Hereditary Cancer Testing
   2. Hereditary Non-cancer Testing
2. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. LAMEA